Anthera Pharmaceuticals (ANTH) Getting Very Favora
Post# of 22757
(Total Views: 282)
Posted On: 06/09/2017 9:17:22 AM
Anthera Pharmaceuticals (ANTH) Getting Very Favorable Media Coverage, Analysis Finds
June 9th, 2017 - By Doug Wharley - 0 comments
Anthera Pharmaceuticals logoNews articles about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended very positive recently, Alpha One Sentiment Analysis reports. The research firm, a unit of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.56 on Alpha One’s scale. Alpha One also gave media stories about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Alpha One’s analysis:
Get Anthera Pharmaceuticals Inc alerts:
Form AW Anthera Pharmaceuticals – StreetInsider.com (streetinsider.com)
Anthera Pharmaceuticals Inc (ANTH) Seeing Increased Action in Session – Stock Press Daily (stockpressdaily.com)
Research Reports Coverage on Biotech Stocks — Anthera Pharma, Cara Therapeutics, Cerus, and Concert Pharma (bizjournals.com)
Anthera Pharmaceuticals Inc (ANTH) Expected to Announce Earnings of -$1.08 Per Share (americanbankingnews.com)
Anthera Pharmaceuticals (ANTH) opened at 1.61 on Friday. Anthera Pharmaceuticals has a 52-week low of $1.54 and a 52-week high of $32.00. The firm has a 50-day moving average price of $1.56 and a 200-day moving average price of $1.05. The company’s market cap is $16.22 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by $0.56. On average, analysts forecast that Anthera Pharmaceuticals will post ($4.95) EPS for the current year.
ANTH has been the topic of a number of recent analyst reports. Jefferies Group LLC reiterated a “hold” rating and issued a $2.25 target price on shares of Anthera Pharmaceuticals in a research report on Monday, May 15th. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $6.00 target price on the stock in a research report on Wednesday, March 8th. Finally, ValuEngine cut Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $10.21.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
June 9th, 2017 - By Doug Wharley - 0 comments
Anthera Pharmaceuticals logoNews articles about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended very positive recently, Alpha One Sentiment Analysis reports. The research firm, a unit of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.56 on Alpha One’s scale. Alpha One also gave media stories about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Alpha One’s analysis:
Get Anthera Pharmaceuticals Inc alerts:
Form AW Anthera Pharmaceuticals – StreetInsider.com (streetinsider.com)
Anthera Pharmaceuticals Inc (ANTH) Seeing Increased Action in Session – Stock Press Daily (stockpressdaily.com)
Research Reports Coverage on Biotech Stocks — Anthera Pharma, Cara Therapeutics, Cerus, and Concert Pharma (bizjournals.com)
Anthera Pharmaceuticals Inc (ANTH) Expected to Announce Earnings of -$1.08 Per Share (americanbankingnews.com)
Anthera Pharmaceuticals (ANTH) opened at 1.61 on Friday. Anthera Pharmaceuticals has a 52-week low of $1.54 and a 52-week high of $32.00. The firm has a 50-day moving average price of $1.56 and a 200-day moving average price of $1.05. The company’s market cap is $16.22 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by $0.56. On average, analysts forecast that Anthera Pharmaceuticals will post ($4.95) EPS for the current year.
ANTH has been the topic of a number of recent analyst reports. Jefferies Group LLC reiterated a “hold” rating and issued a $2.25 target price on shares of Anthera Pharmaceuticals in a research report on Monday, May 15th. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $6.00 target price on the stock in a research report on Wednesday, March 8th. Finally, ValuEngine cut Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $10.21.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
(1)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼